Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 1681

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 10
Chunk 1681
---
  
    $206  
    $(3,271,562) 
    $     (3,271,305)
  
    Net
    income 
     -  
     -  
     -  
     -  
     632,536  
     632,536 
  
    Subsequent
    measurement of ordinary shares subject to possible redemption (interest earned on trust account and extension deposit) 
     -  
     -  
     -  
     -  
     (5,643,271) 
     (5,643,271)
  
    Balance
    as of December 31, 2023 
     510,000  
    $51  
    $2,062,500  
    $206  
    $(8,282,297) 
    $(8,282,040)

The
accompanying notes are an integral part of these consolidated financial statements.

F-6

DENALI
CAPITAL ACQUISITION CORP.

CONSOLIDATED
STATEMENTS OF CASH FLOWS

    For the  
    For the 

    Year Ended  
    Year Ended 

    December 31,  2024  
    December 31,  2023 
  
    Cash flows from operating activities: 

    Net (loss)/income 
    $(167,306) 
    $632,536 
  
    Adjustments to reconcile net (loss)/ income to net cash used in operating activities: 

    Income from Trust 
     (1,578,042) 
     (3,843,271)
  
    Changes in current assets and liabilities: 

    Prepaid Expenses 
     4,976  
     83,113 
  
    Accounts payable and accrued expenses 
     890,833  
     2,457,940 
  
    Accrued interest expense -related party 
     56,534  
     18,021 
  
    Accrued interest expense - others 
     39,709  
     18,878 
  
    Net cash used in operating activities 
     (753,296) 
     (632,783)

    Cash Flows from Investing Activities: 

    Investment held in Trust Account 
     -  
     (825,000)
  
    Cash withdrawn from Trust Account in connection